에 대한 최신 뉴스 Cognex (NASDAQ:CGNX) 주식

Cognex

Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's own cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. ID products read codes that have been applied to items during the manufacturing process. Cognex generates the maximum proportion of its sales in the United States and Europe.

Cognex Corp

Truist Securities analyst Jamie Cook maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Hold and raises the price target from $42 to $43.

News

Price Target

Analyst Ratings

CGNX

Truist Securities Maintains Hold on Cognex, Raises Price Target to $43

Citigroup analyst Piyush Avasthy maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Neutral and lowers the price target from $44 to $42.

Citigroup Maintains Neutral on Cognex, Lowers Price Target to $42

Throughout the last three months, 5 analysts have evaluated Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Cognex and provided 12-month price targets. The average target is $47.2, accompanied by a high estimate of $55.00 and a low estimate of $42.00. This current average represents a 2.68% decrease from the previous average price target of $48.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1735851621_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Cognex's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tommy Moll</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Troy Jensen</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$49.00</td>
<td>-</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$42.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Jamie Cook</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$43.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$47.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Cognex. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cognex compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Cognex's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Cognex's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CGNX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cognex analyst ratings.</a>
<h2>Get to Know Cognex Better</h2>
Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's own cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. ID products read codes that have been applied to items during the manufacturing process. Cognex generates the maximum proportion of its sales in the United States and Europe.
<h3>A Deep Dive into Cognex's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Cognex displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 19.01%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Cognex's net margin is impressive, surpassing industry averages. With a net margin of 12.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Cognex's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.93% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Cognex's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.46% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Cognex's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.05.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Cognex: What You Need To Know

Stephens &amp; Co. analyst Tommy Moll reiterates Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Overweight and maintains $55 price target.

Reiteration

Stephens & Co. Reiterates Overweight on Cognex, Maintains $55 Price Target

Cantor Fitzgerald analyst Troy Jensen initiates coverage on Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Overweight rating and announces Price Target of $49.

Initiation

Cantor Fitzgerald Initiates Coverage On Cognex with Overweight Rating, Announces Price Target of $49

Truist Securities analyst Jamie Cook maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Hold and lowers the price target from $43 to $42.

Truist Securities Maintains Hold on Cognex, Lowers Price Target to $42

Highlighted on November 25, it was unveiled in an SEC filing that Sun, Director at Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>), executed a significant transaction involving the exercise of company stock options.
What Happened: The latest Form 4 filing on Monday with the <a href="https://www.sec.gov/Archives/edgar/data/0000851205/000177370424000011//Archives/edgar/data/851205/000177370424000011/0001773704-24-000011-index.htm">U.S. Securities and Exchange Commission</a> uncovered Sun, Director at Cognex, exercising stock options for 26,000 shares of CGNX. The total transaction was valued at $536,770.
The Tuesday morning update indicates Cognex shares down by 0.63%, currently priced at $41.27. At this value, Sun's 26,000 shares are worth $536,770.
<h3>About Cognex</h3>
Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's own cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. ID products read codes that have been applied to items during the manufacturing process. Cognex generates the maximum proportion of its sales in the United States and Europe.
<h3>A Deep Dive into Cognex's Financials</h3>
Revenue Growth: Over the 3 months period, Cognex showcased positive performance, achieving a revenue growth rate of 19.01% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 67.9%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Cognex's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.17.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.05.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Cognex's current Price to Earnings (P/E) ratio of 81.43 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 8.14 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 54.89, Cognex demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000851205">Check Out The Full List Of Cognex's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Witnessing An Insider Decision, Anthony Sun Exercises Options Valued At $536K At Cognex

WIIM

AEIS

ALGM

ANET

AVGO

AWRE

BELFB

BOXL

CAMT

CLMB

CMTL

CNXN

COHR

CSCO

DELL

DGII

DIOD

EVLV

EXTR

FFIV

FLEX

FORM

FRSH

IONQ

IPGP

KEYS

KODK

LASR

LITE

NOVT

NTAP

NTCT

NVEC

Next Technology Holding Inc. - Ordinary Shares

NXTT

OSIS

PLUS

PLXS

PMTS

PSTG

QMCO

QTWO

SANM

SCSC

SITM

TTMI

VIAV

WOLF

ZBRA

Shares of companies within the broader technology sector are trading higher in sympathy with overall market strength after Donald Trump was elected president of the United States.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58407d80aae83900016b3bd0/bryan-keane">Deutsche Bank analyst Bryan Keane</a> downgraded the rating for Marqeta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) from Buy to Hold and lowered the price target from $9 to $4. Marqeta shares closed at $5.95 on Monday. <a href="https://www.benzinga.com/quote/MQ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Jamie Cook downgraded Cognex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) from Buy to Hold and slashed the price target from $46 to $43. Cognex shares closed at $40.85 on Monday. <a href="https://www.benzinga.com/quote/CGNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Reni Benjamin downgraded the rating for Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) from Market Outperform to Market Perform. Sana Biotechnology shares closed at $3.76 on Monday. <a href="https://www.benzinga.com/quote/SANA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/603e4f87b3e2040001080043/tessa-romero">JP Morgan analyst Tessa Romero</a> downgraded Neumora Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) from Overweight to Neutral and lowered the price target from $18 to $15. Neumora Therapeutics shares closed at $11.71 on Monday. <a href="https://www.benzinga.com/quote/NMRA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Christopher Liu downgraded the rating for IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) from Outperform to Market Perform and lowered the price target from $41 to $27. IDEAYA Biosciences shares closed at $30.00 on Monday. <a href="https://www.benzinga.com/quote/IDYA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CGNX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="533" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-1024x533.png" alt="" class="wp-image-630098" style="width:676px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-1024x533.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27.png 1272w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41740698/top-3-health-care-stocks-youll-regret-missing-in-november">Top 3 Health Care Stocks You&#8217;ll Regret Missing In November</a></li>
</ul>

Downgrades

Pre-Market Outlook

Markets

IDYA

NMRA

SANA

This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Truist Securities analyst Jamie Cook downgrades Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) from Buy to Hold and lowers the price target from $46 to $43.

Truist Securities Downgrades Cognex to Hold, Lowers Price Target to $43

Needham analyst James Ricchiuti maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Buy and lowers the price target from $50 to $47.

Needham Maintains Buy on Cognex, Lowers Price Target to $47

Guidance

Cognex Sees Q4 2024 Revenue $210M-$230M

Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.19 by 5.26 percent. The company reported quarterly sales of $234.74 million which beat the analyst consensus estimate of $233.03 million by 0.74 percent. This is a 19.01 percent increase over sales of $197.24 million the same period last year.

Earnings

Earnings Beats

Cognex Q3 2024 Adj EPS $0.20 Beats $0.19 Estimate, Sales $234.74M Beat $233.03M Estimate

Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">PBF Energy</h3>
<ul>
<li>The Trade: PBF Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBF#NYSE">PBF</a>) 10% owner Control Empresarial de Capitales S.A. de C.V.<a href="https://www.benzinga.com/quote/PBF/analyst-ratings"> acquired a total of 1,210,000 shares at</a> an average price of $33.25. To acquire these shares, it cost around $40.2 million.</li>
<li>What's Happening: PBF Energy will release its earnings results for the third quarter 2024 on Thursday, Oct. 31.</li>
<li>What PBF Energy Does: PBF Energy Inc is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants, and other petroleum products in the United States.</li>
</ul>
<h3 class="wp-block-heading">Talos Energy</h3>
<ul>
<li>The Trade: Talos Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) 10% owner Control Empresarial de Capitales S.A. de C.V. acquired a total of 2,397,000 shares at an average price of $11.08. To acquire these shares, it cost around $26.5 million.</li>
<li>What's Happening: The company disclosed that its Ewing Bank 953 well has successfully discovered commercial quantities of oil and natural gas.</li>
<li>What Talos Energy Does: Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production.</li>
</ul>
<h3 class="wp-block-heading">Cognex</h3>
<ul>
<li>The Trade: Cognex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) SVP, Chief Financial Officer Dennis Fehr <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 6,570 shares</a> at an average price of $38.04. To acquire these shares, it cost around $249,920.</li>
<li>What's Happening: On July 31, Cognex reported mixed second-quarter financial results.</li>
<li>What Cognex Does: Cognex Corp provides machine vision products that help automate manufacturing processes.</li>
</ul>
<h3 class="wp-block-heading">Lululemon Athletica</h3>
<ul>
<li>The Trade: Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) CEO Calvin McDonald <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 4,000 shares</a> at an average price of $260.00. The insider spent around $1.04 million to buy those shares.</li>
<li>What's Happening: On Aug. 29, Lululemon Athletica reported better-than-expected second-quarter EPS results.</li>
<li>What Lululemon Athletica Does: Lululemon Athletica designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls.</li>
</ul>
Check This Out:<a href="https://www.benzinga.com/top-stories/24/09/40730015/jim-cramer-oklo-is-losing-money-hand-over-fist-but-this-private-equity-stock-is-a-buy"> </a>
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40730015/jim-cramer-oklo-is-losing-money-hand-over-fist-but-this-private-equity-stock-is-a-buy">Jim Cramer: Oklo Is Losing Money &#8216;Hand-Over-Fist,&#8217; But This Private Equity Stock Is A Buy</a></li>
</ul>

Long Ideas

LULU

TALO

Over $40M Bet On PBF Energy? Check Out These 4 Stocks Executives Are Buying

AAPL

AEVA

ASNS

BBAI

Core Scientific, Inc. - Class A Common Stock

CORZ

CRSR

DAKT

DOCN

DTST

EGIO

FIVN

GDDY

GTLB

KOPN

LWLG

NSIT

SHOP

SNOW

VECO

Shares of companies within the broader tech sector are trading lower amid overall market weakness. Weakness may be due to August's ISM Manufacturing PMI data indicating an economic contraction.

DA Davidson analyst Matthew Summerville maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Neutral and lowers the price target from $41 to $39.

DA Davidson Maintains Neutral on Cognex, Lowers Price Target to $39

Stephens &amp; Co. analyst Tommy Moll reiterates Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Equal-Weight and maintains $45 price target.

Stephens & Co. Reiterates Equal-Weight on Cognex, Maintains $45 Price Target

ADBE

APLD

BILL

BRZE

CDNS

COMM

DDOG

DOCU

ERIC

ESTC

FSLR

GOOG

GOOGL

INFY

INTC

INTU

IREN

MRVL

MSFT

NTNX

NVDA

OKTA

ORCL

OUST

PANW

PCOR

PLTR

QRVO

SMCI

SMTC

SWKS

TOYO

TRMB

TWLO

VSAT

WDAY

ZETA

Shares of stocks in the broader tech sector are trading lower as stocks sell off amid concerns over the US economy.

Baird analyst Richard Eastman maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Neutral and lowers the price target from $46 to $42.

Baird Maintains Neutral on Cognex, Lowers Price Target to $42

Goldman Sachs analyst Joe Ritchie maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Sell and lowers the price target from $45 to $39.

Goldman Sachs Maintains Sell on Cognex, Lowers Price Target to $39

Cantor Fitzgerald initiated coverage of Cognex (CGNX) with an Overweight rating and $49 price target Published first on TheFly – the ultimate sourc...

Cognex initiated with an Overweight at Cantor Fitzgerald

Impax Global Environmental Markets Fund Q3 2024 Commentary

There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Cognex (CGNX – Research Report) and Nvidia (NVDA – R...

Analysts Offer Insights on Technology Companies: Cognex (CGNX) and Nvidia (NVDA)

Stephens analysts presented the firm's 2025 Best Ideas list, which includes Valley National (VLY), CoStar Group (CSGP), Castle Biosciences (CSTL), ...

Stephens lays out 21 Best Ideas for 2025

LRT Capital Management December 2024 Investor Update

Citi lowered the firm's price target on Cognex (CGNX) to $42 from $44 and keeps a Neutral rating on the shares. The Q4 earnings for industrial cong...

Cognex price target lowered to $42 from $44 at Citi

There's a lot to be optimistic about in the Technology sector as 2 analysts just weighed in on Cognex (CGNX – Research Report) and D-Wave Quantum (...

Analysts Are Bullish on Top Technology Stocks: Cognex (CGNX), D-Wave Quantum (QBTS)

Liberty Park Capital Q4 2024 Letter To Partners

In a report released today, Tommy Moll from Stephens maintained a Buy rating on Cognex (CGNX – Research Report), with a price target of $55.00. The...

Stephens Keeps Their Buy Rating on Cognex (CGNX)

Truist analyst Jamie Cook raised the firm's price target on Cognex (CGNX) to $43 from $42 and keeps a Hold rating on the shares as part of a broade...

Cognex price target raised to $43 from $42 at Truist

ALHC

AMAT

ANDE

ASML

ASMLF

AZPN

AZTA

BMRC

BPMC

BURL

CARR

CASY

CIGI

CSGP

CSTL

CVNA

DECK

DINO

Comments

Cognex

뉴스

에 대한 최신 뉴스 Cognex (NASDAQ:CGNX) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌